SlideShare une entreprise Scribd logo
1  sur  85
GDCA eMarketing Capabilities
            February 9, 2011




        Interactive Experience Experts

                  Confidential
AGENDA




         Confidential
1. Capabilities (Approach & Theory)
         2. Examples of Our Work
         3. Analytics
AGENDA   4. ROI
         5. Message Deployment (Concept)
         6. Next Steps




           Confidential
A GROUNDING THOUGHT AND
        GUIDING PRINCIPLE

                Meaningful bi-directional
Solving brand                               Generating
                conversations with our
 challenges                                  results
                      customers
GROUP DCA OVERVIEW




•   Founded in 1999 by industry veterans         •    Wholly owned subsidiary of PDI, Inc
    Rob Likoff and Jack Davis                    •    65+ full-time employees
•   Creators of award-winning digital            •    Based in Parsippany, NJ
    programs that are proven to drive ROI
•   Design and own proprietary
    software - DIAGRAM Systems
    (Dialogue, Graphics, and Motion)




                                            Confidential
GROUP DCA OVERVIEW


    Leading provider of digital
    solutions for pharmaceutical
    and biotechnology companies


•    Founded in 1999 by industry veterans         •    Wholly owned subsidiary of PDI, Inc
     Rob Likoff and Jack Davis                    •    65+ full-time employees
•    Creators of award-winning digital            •    Based in Parsippany, NJ
     programs that are proven to drive ROI
•    Design and own proprietary
     software - DIAGRAM Systems
     (Dialogue, Graphics, and Motion)




                                             Confidential
GROUP DCA OVERVIEW
GROUP DCA OVERVIEW




Live Reps     Interactive   Peer-to-peer   Voice
GROUP DCA OVERVIEW




Live Reps
        Multi-channel Integration for optimization Voice
                Interactive    Peer-to-peer
Rep Email
                                             Patient
                    Deployment
     Content                                  CRM
                      Systems                          iPad Tablet
    Management
      Systems                                           Content


     eMarketing
                        e-Details                         Mobile Apps
Recruitment, Reach &
Frequency Campaigns                                       Convention
                                                          Experiences
     REMs Online
                                                           Profile &
Interaction & Program
                                                           Segments
     Management
   Field Training                                         Advergaming
                    eSpeaker           eMail Deployment
                               Confidential
Physicians       Pharmacists         Allied Health Professionals




Managed Care   Sales Representatives     Patients & Consumers




                      Confidential
THE CUSTOMER



  Physicians         Pharmacists         Allied Health Professionals




Managed Care     Sales Representatives     Patients & Consumers




                        Confidential
PROMOTIONAL UNBIQUITY

                                                                                                             Use smartphone
                                                                   Check drug                             to look for clinical data
                                                                   information
                                                                    on mobile                  Check e-mail
 Wake Up                                                              device                    Go online
Check e-mail
                      Hospital   Drive to    Read    Receive
                      Rounds      office      Mail      call



am   7         8         9       10         11      12         1        2           3      4          5          6         7     pm
                                                    SEE PATIENTS


                                                                                    See drug rep     Drive to
                                                                                                     hospital         Go online
                                  Start seeing        Go online                                                      Check e-mail
         Drive to                   patients                              Review
                                                     Check e-mail
         Hospital                                                        labs and                      Home for
                                                                           x-rays                       dinner
                                                        Lunch                                           Family
                                                    Personal Calls                                       time
                        Search for
                      information
                    online @ hospital
WOMEN’S HEALTH EXPERIENCE
                             PROGRAMS TARGETED TO OB/GYNS


       Product            eDetailing      eLive      eSpeaker Training   Patient
      Colpexin                X            X                               X
      Ditropan                X
       Divigel                X            X
       Elmiron                X                                            X
       Enjuvia                X
       Famvir                 X                             X
     Menocheck                X            X
     Ortho Evra                                                            X
    Ortho Prefest             X
      Paragard                X
      Premarin                X            X                               X
Premarin Vaginal Cream        X
      Prempro                 X
        Pristiq               X                                            X
        Toviaz                X
HCP DATABASE
         Specialties          Total                Specialties   Total
Allergy/Immunology            1,192    Orthopedic Surgery         5,146
Anesthesiology                6,625    Otolaryngology             967
Cardiology                    7,973    Pain Medicine              1,117
Critical Care/Hospitalist     1,920    Pediatrics                 9,386
Dermatology                   4,267    Physical Medicine          2,362
Emergency Medicine            3,151    Plastic Surgery            6,681
Endocrinology                 1,457    Psychiatry                 9,124
FP/GP                         18,810   Pulmonology                1,234
Gastroenterology              1,983    Radiology                  1,575
Geriatrics                    1,231    Rheumatology              11,434
Hematology                    1,429    Surgery                   13,564
Infectious Disease            1,265    Urology                    2,876
Internal Medicine (general)   23,472   All Other                 35,723
Nephrology                    1,038    Physician Total           216,765
Neurology/NeuroSurgery        11,580
OB/Gyn                        12,024   Podiatry                   174
Oncology & Hem/Onc            10,401   General Dentistry         17,103
Ophthalmology                 5,758    HCP Total                 234,042
OB/GYN 12,000




Confidential
Interactive Content                         HCP Access

                                234,04
DIAGRAM Software   ™
                                  2           OB/GYN 12,000

                                            Database
Dialogue, Graphics & Motion                                        ?   ?
                                                   Convinced   ?
                                                    by Smith
                                                     Study




                              Confidential
CORE PHILOSOPHY
    Superior User Experience
  1:1 Marketing - DIAGRAM™
        Active Learning
        Data & Analytics
The single most important factor in successful
interactive communication is the delivery of a


superior user
experience


                                  Confidential
The single most important factor in successful
interactive communication is the delivery of a


superior user
experience


                                  Confidential
superior user experience
                 Design        Functionality




  “Design is not just what it looks like and feels like.
               Design is how it works.”
                  —Steve Jobs, Apple Inc.
superior user experience
                     Design Functionality




  “Design is not just what it looks like and feels like.
               Design is how it works.”
                  —Steve Jobs, Apple Inc.
Build meaningful relationships with engaging content through

active learning
                                               Passive Learning

                                               10%


                                               * National Institute of Behavior Science




                                 Confidential
Build meaningful relationships with engaging content through

active learning
                                               Passive Learning

                                               10%
                                               Active Learning

                                               75% RETENTION
                                               * National Institute of Behavior Science




                                 Confidential
Applying Learning Theories to Content Creation




                    Confidential
Applying Learning Theories to Content Creation

Cognitive Load Theory
DESIGN THAT OPTIMIZES INTELLECTUAL PERFORMANCE

Dual Coding Theory
RECALL OF IMAGES IS SUPERIOR TO VERBAL CODE ALONE

Experiential Learning Theory
LEARNING BEGINS WITH EXPERIENCE

Adult Learning Theory
ACTIVE INVOLVEMENT IN THE LEARNING PROCESS


                               Confidential
Confidential
Active Learning

product examples
                                Sales Aid Builder™
                                TV Commercial Builder™
                                Strategic Advisor™
                                Website Builder™
                                Reprint Review™
                                Patient Education Builder™
                                Build a Slide Kit™
                                Design a Clinical Study™
                                DTC Advisor™
                                Treatment Algorithm Builder™
                                Formulary Advisor™



                  Confidential
powered by

DIAGRAM Software                   ™
Graphical Data Collection




                                                     Data collection
                                                      for 1:1 dialog
                                                                       Content delivery
                                                                        based on user
              Profile to optimize                                          response
             the user experience




                                       Confidential
powered by

DIAGRAM Software                   ™
Graphical Data Collection




                                                           2
                                                     Data collection          3
                                                      for 1:1 dialog
                     1                                                 Content delivery
                                                                        based on user
              Profile to optimize                                          response
             the user experience




                                       Confidential
Analytics Data Offerings

Dashboards                    Analytical Services
                                                             ?   ?
                                           Convinced
                                          by Riddle MC
                                                         ?
                                             Study




    Real-time answers           Using attitudinal data for HCP
    to interaction data        Segmentation, Profiling, Message
                              Optimization & Predictive Modeling
The Dashboard Tour
The Dashboard Tour
CLOSING THE LOOP
 FOR EFFECTIVE MESSAGE OPTIMIZATION

                          Profile MDs
                          Attitudinally


                                               ID MD
                                              segments
                        Data-Driven           based on
                                                Rx lift
                          insights
   Establish
 ongoing Rx
                       drive relevant
  Intent/MD            Interactions & 
Loyalty Scores         1:1 marketing
                                             ID segment
                                              attitudinal
                                               drivers
        Optimize 1:1
         marketing               Create
                             insight-based
                               message
                              refinement
EXAMPLE: BEST CUSTOMER PROFILE
 24%                  Is in large community with over 25 Pain Patients per month
            49%       Less fear of patient addiction
 27%                  Uses pain rating scales
                      Aggressive early treater
   Pain Specialists
   PCP’s
                      Post-op & Back pain patients
   Orthopods          Find Hartrick Study believable and relevant
                      E & T message resonates esp with Pain Specialists
Loyalty Index
                      “Best Customer” insights suggest:


 76                   MDs as profiled have shown propensity to Rx more
                      Brand X post eDetail and will have high Brand Loyalty scores
                      given time on market.
GAIN INSIGHT
GAIN INSIGHT




        Integration to Digital Hub

                              •   Refine future messaging
                              •   Inform other tactics
                              •   Channel preferences


PDI Channels are tracked by unique HCP ID
ROI OF SELECTED PROGRAMS
                        BY THERAPEUTIC CATEGORY*

               Therapeutic category                             ROI @ 12 months
                Alzheimer’s disease                                  4.6 : 1
                  Antibiotic – oral                                  8.2 : 1
       Breast cancer – hormonal therapy                              6.2 : 1
                   Herpes therapy                                    3.1 : 1
        Hormone replacement therapy                                 12.9 : 1
                       Migraine                                      3.3 : 1
                    Pain – Acute                                     6.5 : 1
                   Pain – Chronic                                    5.4 : 1
                  Multiple sclerosis                                16.7 : 1

*Identification of selected brands may be available on request
ROI SIMULATION
                16
                             ALL
                14           decile 10
                             decile 9
% Return (00)




                12           decile 8
                             decile 7
                10


                 8


                 6


                 4


                 2


                 0
                     1   2           3      4    5     6      7   8   9


                                           % Increase in Rx
IMPACT: ROI EXAMPLES


• Chronic Pain

• Alzheimer’s Disease

• Migraine

• Anti-Infective
CHRONIC PAIN PROGRAM SNAPSHOT



•3 eDetail waves/                  • Expansion   program
 5 mail waves
                                    • Additional 20,000
• Original   program                  mail targets

  • 20,000    mail targets          • Additional2,500
                                      eDetail completions
  • 2,500    eDetail completions
Ultram ER-TEST
  CHRONIC PAIN RESULTS                                                       Ultram ER-CONTROL

1.50




1.13




0.75
                                     Program
                                      Starts
0.38


                                                                             Significant @ 99% Confidence
  0
       -5     -4      -3     -2        -1        0       1      2       3    4      5        6       7

  •    1-3 eDetail waves completed          •   6-month ROI: 651% or 7.5:1
  •    98.4% NRx increase                   •   12-month ROI (proj) 1908%
ALZHEIMER’S DISEASE PROGRAM SNAPSHOT



• 3 eDetail waves/              • Three Expansions
  3 mail waves
                                  – 25,000 additional targets
• Original program
                                  – 5,000 additional
  – 17,500 targets                  completions

  – 2,500 eDetail completions
Razadyne ER-TEST
   ALZHEIMER’S DISEASE RESULTS                                                     Razadyne ER-CONTROL

0.70




0.53




0.35




0.18
                              Program
                               Starts                                              Significant @ 99% Confidence
  0
       -5   -4    -3   -2    -1    0   1       2      3    4    5   6    7     8     9    10    11   12    13

  •     3 eDetail / 3 mail waves           •   12-month ROI: 760% or 8.5:1
  •     68.9% NRx increase                 •       24-month ROI (proj) 1120%
MIGRAINE CATEGORY PROGRAM SNAPSHOT



• 3 eDetail waves/              • Expansion program
  4 mail waves
                                  – More content
• Original Program
                                • VIP program – in progress
  – 12,500 mail targets

  – 2,000 eDetail completions
Axert-TEST
  MIGRAINE PROGRAM SNAPSHOT                                                          Axert-CONTROL

0.90




0.68




0.45
                                     Program
                                      Starts
0.23


                                                                                 Significant @ 95% Confidence
  0
       Sep   Oct   Nov   Dec   Jan     Feb   Mar     Apr   May   Jun   Jul     Aug    Sept   Oct   Nov   Dec

  •    3 eDetail / 4 mail waves (n=722)        •   12-month ROI: 334% or 4.3:1
  •    55.3% NRx increase                      •   18-month ROI (proj): 668%
ANTIBIOTIC PROGRAM SNAPSHOT



• 3 eDetail waves/              • Expansion program
  4 mail waves
                                  – More content
• Original Program
                                • VIP program – in progress
  – 20,000 mail targets

  – 3,000 eDetail completions
Levaquin-TEST
  ANTIBIOTIC RESULTS                                                                Levaquin-CONTROL

9.00




6.75




4.50




2.25


                                                                                Significant @ 99% Confidence
  0
       -5    -4   -3    -2    -1     0    1       2    3     4     5    6       7     8     9     10    11

  •    3 eDetail / 4 mail waves (n=949)       •   12-month ROI: 734% or 8.3:1
  •    86.7% NRx increase
DEMO
CASE STUDY
                Channel Effectiveness
Synergistic effect between Live Reps and eDetailing




          +                       =         Rx
                                            Lift
PRODUCT CHANNEL EFFECTIVENESS
                                   SYNERGISTIC EFFECT INCREASED AVG. # OF PRODUCT
                                        PATIENTS BY 60% OVER REP CALL ALONE
                15

                                Highest
                12
                              among MDs
                            receiving rep call
                              and eDetail
                 9
# of patients




                               promotion

                 6
                                    6.0
                 3
                                                    60% Synergistic effect
                                                                           2.4
                                                         1.5                            1.0
                 0
                                 eDetail/           eDetail Only         Rep Detail   No Detail     No Detail
                                Rep Detail            n=31                  Only       n=126      (non-called on)
                                  n=68                                     n=171
                Source: Message Recall (Wave 2), January/February 2009
                Base: Total unique physicians, *Less than 0.5%
PRODUCT CHANNEL EFFECTIVENESS
            REPS WERE ENGAGED TO DRIVE EDETAIL PARTICIPATION




Situation:
Opportunity to boost PRODUCT X
market share in a district


                                            39%
Multi-Channel Tactic:
Team deployed eDetail with market’s
top urologists on a weekly basis
Results:
Over 13 week period territory
                                             Rx lift
experienced an Rx lift from 19
scripts to 28 scripts among 7
urologists participating in the eDetail    Rep + eDetail
NUCYNTA (TAPENTADOL)
BRAND
                                    SOLUTION
    OBJECTIVES
• “Disrupt” the   Pain Market   • NeoPathways—Disease
                                 State Education Program
• Reinforce
         that pain
 management is often            • Comprehensive,
 under managed                   multichannel, multi-module
                                 communication program
• Providescientific data
 supporting chronicity of       • Synergistic
                                            sales
 pain concept                    force program
• 6-wave pre-launch campaign
  – Highlight challenges in pain management
  – Create a baseline of INDIVIDUAL physician attitudes re:
    under treatment of pain
  – Generate awareness around core issues in pain management
  – DISRUPT Market & existing habits
RESULTS

>20,000          >55,000          18 min.            >90%
    unique       total modules   Average time per      opt-in for
  participants     reviewed         participant     branded launch



• Significant increase in awareness of key brand issues,
  e.g. dual MOA
• Participants had a significant higher uptake at launch
NEOPATHWAYS EDETAILING PROGRAM:
CUMULATIVE PARTICIPATION SINCE LAUNCH
        PRICARA REPS (05/15/09)
TACTICAL IMPLEMENTATION
TACTICAL IMPLEMENTATION
LAUNCH RESULTS
• Prior
      to seeing any brand data, HCPs were presented with 3 patient
 profiles and were asked what medication they would prescribe.

                                                          Before reviewing After reviewing
  3 Patient Profiles                                         Nucynta data    Nucynta data

  Middle age male, former athlete, acute low back pain,
  currently self treating with NSAIDs, no other            52% chose        65% chose
  significant medical history, receiving no additional       Vicodin          Nucynta
  medications

  Middle age female, acute post-op hip replacement
                                                           46% chose        65% chose
  with moderate intermittent pain, no other significant
  medical history, receiving no additional medications      Vicodin          Nucynta

  Male, late 30’s, car crash survivor, severe shoulder
  injury/trauma and pain, no other significant medical      37% chose        64% chose
  history, on no other regular medical therapy              Vicodin          Nucynta
PRE-LAUNCH EDETAIL CAMPAIGN SIGNIFICANTLY
      ACCELERATED UPTAKE AT LAUNCH
                                                     2009 Nucynta - Group DCA e-detailing Program
                                                                        ALL Doctors N=3,432
                                                  Change in Nucynta NRxs/MD (Prelaunch eDetails vs Control) = 131.0%
                                                                     Significant @ 99% Confidence



                           2.50




                           2.00
 Nucynta NRxs per doctor




                           1.50
                                                                                                                                 Nucynta-Prelaunch
                                                                                                                                 eDetails


                           1.00




                           0.50




                           0.00
                                  1   2   3   4       5    6    7     8    9     10     11   12   13   14   15   16    17   18
                                                                               Period
COBAS HPV TEST
        PROPOSED MESSAGING
         TWELVE CALL PLAN
Month                  Primary Message                                          Objective

  1              Introduction to Roche Diagnostics                          Service/Relationship

  2                Launch Detail: cobas HPV Test                 Introduce the benefits of the cobas HPV Test

  3                  ATHENA: In-depth review                  Communicate importance of the study, GT 16 & 18

  4                 HPV: Why test women >30                                  Market expansion

  5               Why specify the cobas HPV Test:                        Branding/brand specification

  6          How to talk to patients about the HPV test                     Service/Relationship

  7            Importance of GT 16/18 as risk factors                            Education

  8       Benefits of cobas HPV test to HCPs, labs, patients              Branding/brand specification

  9                  HPV test guideline review                               Market expansion

 10                cobas HPV test v. Competition                         Branding/brand specification

 11                 ATHENA Trial: sub-analyses                           Branding/brand specification

 12                    HPV: Myths and Facts                                  Market expansion
COBAS HPV TEST
        ONLINE MESSAGING
           OVERVIEW
Month                        e-Mail                                          e-Detail

  1             Introduction to Roche Diagnostics

  2               Launch Detail: cobas HPV Test              Introduce the benefits of the cobas HPV Test

  3                 ATHENA: In-depth review

  4                HPV: Why test women >30

  5              Why specify the cobas HPV Test:

  6         How to talk to patients about the HPV test       How to talk to patients about the HPV test

  7           Importance of GT 16/18 as risk factors

  8      Benefits of cobas HPV test to HCPs, labs, patients

  9                 HPV test guideline review                         HPV test guideline review

 10               cobas HPV test v. Competition

 11                ATHENA Trial: sub-analyses

 12                   HPV: Myths and Facts                              HPV: Myths and Facts
Tactics                                               Qty     Cost    Total

eDetailing Sessions 4 waves at 85K
•2 Full 5 Minute Sessions (Est. $85K)                  4      73750    $295,000
•2 Mini (2-3) Minute Session (Est $62.5K)
eDetailing eMails                                      12     7200      $86,400
Supplemental email recruitment
                                                       8      3500      $28,000
•2 emails per wave
eMail Broadcasts (12,000 x 12)                       144000   0.45      $64,800

Direct Mail/Web Key (recruitment)                    24000    3.50      $84,000

iPad/Tablet Details for Reps                           1      85000     $85,000

iPhone App                                             1      42500     $42,500

Total                                                                 $685,700



                                       Confidential
Interactive Experience Experts




           Confidential

Contenu connexe

En vedette

Innovation drives expansion, Titus Gylvin
Innovation drives expansion, Titus Gylvin Innovation drives expansion, Titus Gylvin
Innovation drives expansion, Titus Gylvin Business Turku
 
Roche diagnostics sales planning
Roche diagnostics   sales planning Roche diagnostics   sales planning
Roche diagnostics sales planning Tridant
 
Case question of roche
Case question of rocheCase question of roche
Case question of rocheBimo Radityo
 
Conference brochure
Conference brochureConference brochure
Conference brochurepzikanga
 
Powerpointpresentatie Roche Diagnostics
Powerpointpresentatie Roche DiagnosticsPowerpointpresentatie Roche Diagnostics
Powerpointpresentatie Roche Diagnosticsalltextpower
 
Digital Pathology streamlines tissue diagnostics and helps protect patient sa...
Digital Pathology streamlines tissue diagnostics and helps protect patient sa...Digital Pathology streamlines tissue diagnostics and helps protect patient sa...
Digital Pathology streamlines tissue diagnostics and helps protect patient sa...Roche Tissue Diagnostics
 
Roche Diagnostics
Roche DiagnosticsRoche Diagnostics
Roche Diagnosticslove4mihir
 
Roche's Acquisition of Genentech
Roche's Acquisition of GenentechRoche's Acquisition of Genentech
Roche's Acquisition of GenentechYu Cao
 

En vedette (9)

Innovation drives expansion, Titus Gylvin
Innovation drives expansion, Titus Gylvin Innovation drives expansion, Titus Gylvin
Innovation drives expansion, Titus Gylvin
 
Roche diagnostics sales planning
Roche diagnostics   sales planning Roche diagnostics   sales planning
Roche diagnostics sales planning
 
Case question of roche
Case question of rocheCase question of roche
Case question of roche
 
Conference brochure
Conference brochureConference brochure
Conference brochure
 
Powerpointpresentatie Roche Diagnostics
Powerpointpresentatie Roche DiagnosticsPowerpointpresentatie Roche Diagnostics
Powerpointpresentatie Roche Diagnostics
 
Digital Pathology streamlines tissue diagnostics and helps protect patient sa...
Digital Pathology streamlines tissue diagnostics and helps protect patient sa...Digital Pathology streamlines tissue diagnostics and helps protect patient sa...
Digital Pathology streamlines tissue diagnostics and helps protect patient sa...
 
Rodney POC
Rodney POCRodney POC
Rodney POC
 
Roche Diagnostics
Roche DiagnosticsRoche Diagnostics
Roche Diagnostics
 
Roche's Acquisition of Genentech
Roche's Acquisition of GenentechRoche's Acquisition of Genentech
Roche's Acquisition of Genentech
 

Similaire à Roche diagnostics 2 9-11 - no speaker notes

Physician research & communications
Physician research & communicationsPhysician research & communications
Physician research & communicationsKevin Nalty
 
Digital Health Presentation
Digital Health PresentationDigital Health Presentation
Digital Health PresentationSteven Peskin
 
Wiredandwireless2 12656614569424 Phpapp02[1]
Wiredandwireless2 12656614569424 Phpapp02[1]Wiredandwireless2 12656614569424 Phpapp02[1]
Wiredandwireless2 12656614569424 Phpapp02[1]caprittim
 
iDialog.in - Work Showcase
iDialog.in -  Work ShowcaseiDialog.in -  Work Showcase
iDialog.in - Work Showcasegothamraja
 
ERP software for Doctor. Complete management software for hospital.
ERP software for Doctor.  Complete management software for hospital.ERP software for Doctor.  Complete management software for hospital.
ERP software for Doctor. Complete management software for hospital.Jyotindra Zaveri
 
U.S. Sales Communications Excellence: Resources, Structure and Processes to O...
U.S. Sales Communications Excellence: Resources, Structure and Processes to O...U.S. Sales Communications Excellence: Resources, Structure and Processes to O...
U.S. Sales Communications Excellence: Resources, Structure and Processes to O...Best Practices
 
U.S. Sales Communications Excellence: Resources, Structure and Processes to O...
U.S. Sales Communications Excellence: Resources, Structure and Processes to O...U.S. Sales Communications Excellence: Resources, Structure and Processes to O...
U.S. Sales Communications Excellence: Resources, Structure and Processes to O...Marty Daniel with ThunderActive
 
Futures health informatics briefing intel aug 2011
Futures health informatics briefing intel  aug 2011Futures health informatics briefing intel  aug 2011
Futures health informatics briefing intel aug 2011bobjay
 
Step-by-step Physician Marketing
Step-by-step Physician MarketingStep-by-step Physician Marketing
Step-by-step Physician MarketingEndeavor Management
 
Open app challenge phase 1 submission Rapid Consulting-Mothers Milk app
Open app challenge phase 1 submission Rapid Consulting-Mothers Milk appOpen app challenge phase 1 submission Rapid Consulting-Mothers Milk app
Open app challenge phase 1 submission Rapid Consulting-Mothers Milk appAnton Ansalmar
 
Project HealthDesign -Technical Architecture Diagrams
Project HealthDesign -Technical Architecture DiagramsProject HealthDesign -Technical Architecture Diagrams
Project HealthDesign -Technical Architecture DiagramsProject HealthDesign
 
If NOT for “meaningful use”, then…….Why?
If NOT for “meaningful use”, then…….Why?If NOT for “meaningful use”, then…….Why?
If NOT for “meaningful use”, then…….Why?slvhit
 
Findhealth
FindhealthFindhealth
FindhealthAnna Jo
 
VerifyEMR Overview March 2012
VerifyEMR Overview March 2012VerifyEMR Overview March 2012
VerifyEMR Overview March 2012Jim Metropoulos
 

Similaire à Roche diagnostics 2 9-11 - no speaker notes (20)

Physician research & communications
Physician research & communicationsPhysician research & communications
Physician research & communications
 
Digital Health Presentation
Digital Health PresentationDigital Health Presentation
Digital Health Presentation
 
Wiredandwireless2 12656614569424 Phpapp02[1]
Wiredandwireless2 12656614569424 Phpapp02[1]Wiredandwireless2 12656614569424 Phpapp02[1]
Wiredandwireless2 12656614569424 Phpapp02[1]
 
iDialog.in - Work Showcase
iDialog.in -  Work ShowcaseiDialog.in -  Work Showcase
iDialog.in - Work Showcase
 
ERP software for Doctor. Complete management software for hospital.
ERP software for Doctor.  Complete management software for hospital.ERP software for Doctor.  Complete management software for hospital.
ERP software for Doctor. Complete management software for hospital.
 
U.S. Sales Communications Excellence: Resources, Structure and Processes to O...
U.S. Sales Communications Excellence: Resources, Structure and Processes to O...U.S. Sales Communications Excellence: Resources, Structure and Processes to O...
U.S. Sales Communications Excellence: Resources, Structure and Processes to O...
 
U.S. Sales Communications Excellence: Resources, Structure and Processes to O...
U.S. Sales Communications Excellence: Resources, Structure and Processes to O...U.S. Sales Communications Excellence: Resources, Structure and Processes to O...
U.S. Sales Communications Excellence: Resources, Structure and Processes to O...
 
Futures health informatics briefing intel aug 2011
Futures health informatics briefing intel  aug 2011Futures health informatics briefing intel  aug 2011
Futures health informatics briefing intel aug 2011
 
Step-by-step Physician Marketing
Step-by-step Physician MarketingStep-by-step Physician Marketing
Step-by-step Physician Marketing
 
Healthcare business intelligence
Healthcare business intelligenceHealthcare business intelligence
Healthcare business intelligence
 
MedITEX IVF Product Presentation
MedITEX IVF Product PresentationMedITEX IVF Product Presentation
MedITEX IVF Product Presentation
 
Open app challenge phase 1 submission Rapid Consulting-Mothers Milk app
Open app challenge phase 1 submission Rapid Consulting-Mothers Milk appOpen app challenge phase 1 submission Rapid Consulting-Mothers Milk app
Open app challenge phase 1 submission Rapid Consulting-Mothers Milk app
 
eDiscovery Infographic
eDiscovery InfographiceDiscovery Infographic
eDiscovery Infographic
 
Project HealthDesign -Technical Architecture Diagrams
Project HealthDesign -Technical Architecture DiagramsProject HealthDesign -Technical Architecture Diagrams
Project HealthDesign -Technical Architecture Diagrams
 
Salesforce ecollab himss2 copy
Salesforce ecollab himss2 copySalesforce ecollab himss2 copy
Salesforce ecollab himss2 copy
 
The big data - canvas-friday
The big data - canvas-fridayThe big data - canvas-friday
The big data - canvas-friday
 
If NOT for “meaningful use”, then…….Why?
If NOT for “meaningful use”, then…….Why?If NOT for “meaningful use”, then…….Why?
If NOT for “meaningful use”, then…….Why?
 
Findhealth
FindhealthFindhealth
Findhealth
 
Sesame 24-7 Online Patient Portal
Sesame 24-7 Online Patient PortalSesame 24-7 Online Patient Portal
Sesame 24-7 Online Patient Portal
 
VerifyEMR Overview March 2012
VerifyEMR Overview March 2012VerifyEMR Overview March 2012
VerifyEMR Overview March 2012
 

Roche diagnostics 2 9-11 - no speaker notes

  • 1. GDCA eMarketing Capabilities February 9, 2011 Interactive Experience Experts Confidential
  • 2. AGENDA Confidential
  • 3. 1. Capabilities (Approach & Theory) 2. Examples of Our Work 3. Analytics AGENDA 4. ROI 5. Message Deployment (Concept) 6. Next Steps Confidential
  • 4. A GROUNDING THOUGHT AND GUIDING PRINCIPLE Meaningful bi-directional Solving brand Generating conversations with our challenges results customers
  • 5. GROUP DCA OVERVIEW • Founded in 1999 by industry veterans • Wholly owned subsidiary of PDI, Inc Rob Likoff and Jack Davis • 65+ full-time employees • Creators of award-winning digital • Based in Parsippany, NJ programs that are proven to drive ROI • Design and own proprietary software - DIAGRAM Systems (Dialogue, Graphics, and Motion) Confidential
  • 6. GROUP DCA OVERVIEW Leading provider of digital solutions for pharmaceutical and biotechnology companies • Founded in 1999 by industry veterans • Wholly owned subsidiary of PDI, Inc Rob Likoff and Jack Davis • 65+ full-time employees • Creators of award-winning digital • Based in Parsippany, NJ programs that are proven to drive ROI • Design and own proprietary software - DIAGRAM Systems (Dialogue, Graphics, and Motion) Confidential
  • 8. GROUP DCA OVERVIEW Live Reps Interactive Peer-to-peer Voice
  • 9. GROUP DCA OVERVIEW Live Reps Multi-channel Integration for optimization Voice Interactive Peer-to-peer
  • 10. Rep Email Patient Deployment Content CRM Systems iPad Tablet Management Systems Content eMarketing e-Details Mobile Apps Recruitment, Reach & Frequency Campaigns Convention Experiences REMs Online Profile & Interaction & Program Segments Management Field Training Advergaming eSpeaker eMail Deployment Confidential
  • 11. Physicians Pharmacists Allied Health Professionals Managed Care Sales Representatives Patients & Consumers Confidential
  • 12. THE CUSTOMER Physicians Pharmacists Allied Health Professionals Managed Care Sales Representatives Patients & Consumers Confidential
  • 13. PROMOTIONAL UNBIQUITY Use smartphone Check drug to look for clinical data information on mobile Check e-mail Wake Up device Go online Check e-mail Hospital Drive to Read Receive Rounds office Mail call am 7 8 9 10 11 12 1 2 3 4 5 6 7 pm SEE PATIENTS See drug rep Drive to hospital Go online Start seeing Go online Check e-mail Drive to patients Review Check e-mail Hospital labs and Home for x-rays dinner Lunch Family Personal Calls time Search for information online @ hospital
  • 14. WOMEN’S HEALTH EXPERIENCE PROGRAMS TARGETED TO OB/GYNS Product eDetailing eLive eSpeaker Training Patient Colpexin X X X Ditropan X Divigel X X Elmiron X X Enjuvia X Famvir X X Menocheck X X Ortho Evra X Ortho Prefest X Paragard X Premarin X X X Premarin Vaginal Cream X Prempro X Pristiq X X Toviaz X
  • 15. HCP DATABASE Specialties Total Specialties Total Allergy/Immunology 1,192 Orthopedic Surgery 5,146 Anesthesiology 6,625 Otolaryngology 967 Cardiology 7,973 Pain Medicine 1,117 Critical Care/Hospitalist 1,920 Pediatrics 9,386 Dermatology 4,267 Physical Medicine 2,362 Emergency Medicine 3,151 Plastic Surgery 6,681 Endocrinology 1,457 Psychiatry 9,124 FP/GP 18,810 Pulmonology 1,234 Gastroenterology 1,983 Radiology 1,575 Geriatrics 1,231 Rheumatology 11,434 Hematology 1,429 Surgery 13,564 Infectious Disease 1,265 Urology 2,876 Internal Medicine (general) 23,472 All Other 35,723 Nephrology 1,038 Physician Total 216,765 Neurology/NeuroSurgery 11,580 OB/Gyn 12,024 Podiatry 174 Oncology & Hem/Onc 10,401 General Dentistry 17,103 Ophthalmology 5,758 HCP Total 234,042
  • 17. Interactive Content HCP Access 234,04 DIAGRAM Software ™ 2 OB/GYN 12,000 Database Dialogue, Graphics & Motion ? ? Convinced ? by Smith Study Confidential
  • 18. CORE PHILOSOPHY Superior User Experience 1:1 Marketing - DIAGRAM™ Active Learning Data & Analytics
  • 19. The single most important factor in successful interactive communication is the delivery of a superior user experience Confidential
  • 20. The single most important factor in successful interactive communication is the delivery of a superior user experience Confidential
  • 21. superior user experience Design Functionality “Design is not just what it looks like and feels like. Design is how it works.” —Steve Jobs, Apple Inc.
  • 22. superior user experience Design Functionality “Design is not just what it looks like and feels like. Design is how it works.” —Steve Jobs, Apple Inc.
  • 23. Build meaningful relationships with engaging content through active learning Passive Learning 10% * National Institute of Behavior Science Confidential
  • 24. Build meaningful relationships with engaging content through active learning Passive Learning 10% Active Learning 75% RETENTION * National Institute of Behavior Science Confidential
  • 25. Applying Learning Theories to Content Creation Confidential
  • 26. Applying Learning Theories to Content Creation Cognitive Load Theory DESIGN THAT OPTIMIZES INTELLECTUAL PERFORMANCE Dual Coding Theory RECALL OF IMAGES IS SUPERIOR TO VERBAL CODE ALONE Experiential Learning Theory LEARNING BEGINS WITH EXPERIENCE Adult Learning Theory ACTIVE INVOLVEMENT IN THE LEARNING PROCESS Confidential
  • 28. Active Learning product examples Sales Aid Builder™ TV Commercial Builder™ Strategic Advisor™ Website Builder™ Reprint Review™ Patient Education Builder™ Build a Slide Kit™ Design a Clinical Study™ DTC Advisor™ Treatment Algorithm Builder™ Formulary Advisor™ Confidential
  • 29. powered by DIAGRAM Software ™ Graphical Data Collection Data collection for 1:1 dialog Content delivery based on user Profile to optimize response the user experience Confidential
  • 30. powered by DIAGRAM Software ™ Graphical Data Collection 2 Data collection 3 for 1:1 dialog 1 Content delivery based on user Profile to optimize response the user experience Confidential
  • 31.
  • 32. Analytics Data Offerings Dashboards Analytical Services ? ? Convinced by Riddle MC ? Study Real-time answers Using attitudinal data for HCP to interaction data Segmentation, Profiling, Message Optimization & Predictive Modeling
  • 35.
  • 36. CLOSING THE LOOP FOR EFFECTIVE MESSAGE OPTIMIZATION Profile MDs Attitudinally ID MD segments Data-Driven based on Rx lift insights Establish ongoing Rx drive relevant Intent/MD Interactions &  Loyalty Scores 1:1 marketing ID segment attitudinal drivers Optimize 1:1 marketing Create insight-based message refinement
  • 37. EXAMPLE: BEST CUSTOMER PROFILE 24% Is in large community with over 25 Pain Patients per month 49% Less fear of patient addiction 27% Uses pain rating scales Aggressive early treater Pain Specialists PCP’s Post-op & Back pain patients Orthopods Find Hartrick Study believable and relevant E & T message resonates esp with Pain Specialists Loyalty Index “Best Customer” insights suggest: 76 MDs as profiled have shown propensity to Rx more Brand X post eDetail and will have high Brand Loyalty scores given time on market.
  • 39. GAIN INSIGHT Integration to Digital Hub • Refine future messaging • Inform other tactics • Channel preferences PDI Channels are tracked by unique HCP ID
  • 40. ROI OF SELECTED PROGRAMS BY THERAPEUTIC CATEGORY* Therapeutic category ROI @ 12 months Alzheimer’s disease 4.6 : 1 Antibiotic – oral 8.2 : 1 Breast cancer – hormonal therapy 6.2 : 1 Herpes therapy 3.1 : 1 Hormone replacement therapy 12.9 : 1 Migraine 3.3 : 1 Pain – Acute 6.5 : 1 Pain – Chronic 5.4 : 1 Multiple sclerosis 16.7 : 1 *Identification of selected brands may be available on request
  • 41. ROI SIMULATION 16 ALL 14 decile 10 decile 9 % Return (00) 12 decile 8 decile 7 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 % Increase in Rx
  • 42. IMPACT: ROI EXAMPLES • Chronic Pain • Alzheimer’s Disease • Migraine • Anti-Infective
  • 43. CHRONIC PAIN PROGRAM SNAPSHOT •3 eDetail waves/ • Expansion program 5 mail waves • Additional 20,000 • Original program mail targets • 20,000 mail targets • Additional2,500 eDetail completions • 2,500 eDetail completions
  • 44. Ultram ER-TEST CHRONIC PAIN RESULTS Ultram ER-CONTROL 1.50 1.13 0.75 Program Starts 0.38 Significant @ 99% Confidence 0 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 • 1-3 eDetail waves completed • 6-month ROI: 651% or 7.5:1 • 98.4% NRx increase • 12-month ROI (proj) 1908%
  • 45. ALZHEIMER’S DISEASE PROGRAM SNAPSHOT • 3 eDetail waves/ • Three Expansions 3 mail waves – 25,000 additional targets • Original program – 5,000 additional – 17,500 targets completions – 2,500 eDetail completions
  • 46. Razadyne ER-TEST ALZHEIMER’S DISEASE RESULTS Razadyne ER-CONTROL 0.70 0.53 0.35 0.18 Program Starts Significant @ 99% Confidence 0 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 • 3 eDetail / 3 mail waves • 12-month ROI: 760% or 8.5:1 • 68.9% NRx increase • 24-month ROI (proj) 1120%
  • 47. MIGRAINE CATEGORY PROGRAM SNAPSHOT • 3 eDetail waves/ • Expansion program 4 mail waves – More content • Original Program • VIP program – in progress – 12,500 mail targets – 2,000 eDetail completions
  • 48. Axert-TEST MIGRAINE PROGRAM SNAPSHOT Axert-CONTROL 0.90 0.68 0.45 Program Starts 0.23 Significant @ 95% Confidence 0 Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sept Oct Nov Dec • 3 eDetail / 4 mail waves (n=722) • 12-month ROI: 334% or 4.3:1 • 55.3% NRx increase • 18-month ROI (proj): 668%
  • 49. ANTIBIOTIC PROGRAM SNAPSHOT • 3 eDetail waves/ • Expansion program 4 mail waves – More content • Original Program • VIP program – in progress – 20,000 mail targets – 3,000 eDetail completions
  • 50. Levaquin-TEST ANTIBIOTIC RESULTS Levaquin-CONTROL 9.00 6.75 4.50 2.25 Significant @ 99% Confidence 0 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11 • 3 eDetail / 4 mail waves (n=949) • 12-month ROI: 734% or 8.3:1 • 86.7% NRx increase
  • 51.
  • 52.
  • 53. DEMO
  • 54. CASE STUDY Channel Effectiveness Synergistic effect between Live Reps and eDetailing + = Rx Lift
  • 55. PRODUCT CHANNEL EFFECTIVENESS SYNERGISTIC EFFECT INCREASED AVG. # OF PRODUCT PATIENTS BY 60% OVER REP CALL ALONE 15 Highest 12 among MDs receiving rep call and eDetail 9 # of patients promotion 6 6.0 3 60% Synergistic effect 2.4 1.5 1.0 0 eDetail/ eDetail Only Rep Detail No Detail No Detail Rep Detail n=31 Only n=126 (non-called on) n=68 n=171 Source: Message Recall (Wave 2), January/February 2009 Base: Total unique physicians, *Less than 0.5%
  • 56. PRODUCT CHANNEL EFFECTIVENESS REPS WERE ENGAGED TO DRIVE EDETAIL PARTICIPATION Situation: Opportunity to boost PRODUCT X market share in a district 39% Multi-Channel Tactic: Team deployed eDetail with market’s top urologists on a weekly basis Results: Over 13 week period territory Rx lift experienced an Rx lift from 19 scripts to 28 scripts among 7 urologists participating in the eDetail Rep + eDetail
  • 58. BRAND SOLUTION OBJECTIVES • “Disrupt” the Pain Market • NeoPathways—Disease State Education Program • Reinforce that pain management is often • Comprehensive, under managed multichannel, multi-module communication program • Providescientific data supporting chronicity of • Synergistic sales pain concept force program
  • 59.
  • 60.
  • 61. • 6-wave pre-launch campaign – Highlight challenges in pain management – Create a baseline of INDIVIDUAL physician attitudes re: under treatment of pain – Generate awareness around core issues in pain management – DISRUPT Market & existing habits
  • 62.
  • 63.
  • 64.
  • 65.
  • 66.
  • 67.
  • 68.
  • 69.
  • 70.
  • 71.
  • 72.
  • 73.
  • 74. RESULTS >20,000 >55,000 18 min. >90% unique total modules Average time per opt-in for participants reviewed participant branded launch • Significant increase in awareness of key brand issues, e.g. dual MOA • Participants had a significant higher uptake at launch
  • 75. NEOPATHWAYS EDETAILING PROGRAM: CUMULATIVE PARTICIPATION SINCE LAUNCH PRICARA REPS (05/15/09)
  • 78.
  • 79.
  • 80. LAUNCH RESULTS • Prior to seeing any brand data, HCPs were presented with 3 patient profiles and were asked what medication they would prescribe. Before reviewing After reviewing 3 Patient Profiles Nucynta data Nucynta data Middle age male, former athlete, acute low back pain, currently self treating with NSAIDs, no other 52% chose 65% chose significant medical history, receiving no additional Vicodin Nucynta medications Middle age female, acute post-op hip replacement 46% chose 65% chose with moderate intermittent pain, no other significant medical history, receiving no additional medications Vicodin Nucynta Male, late 30’s, car crash survivor, severe shoulder injury/trauma and pain, no other significant medical 37% chose 64% chose history, on no other regular medical therapy Vicodin Nucynta
  • 81. PRE-LAUNCH EDETAIL CAMPAIGN SIGNIFICANTLY ACCELERATED UPTAKE AT LAUNCH 2009 Nucynta - Group DCA e-detailing Program ALL Doctors N=3,432 Change in Nucynta NRxs/MD (Prelaunch eDetails vs Control) = 131.0% Significant @ 99% Confidence 2.50 2.00 Nucynta NRxs per doctor 1.50 Nucynta-Prelaunch eDetails 1.00 0.50 0.00 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Period
  • 82. COBAS HPV TEST PROPOSED MESSAGING TWELVE CALL PLAN Month Primary Message Objective 1 Introduction to Roche Diagnostics Service/Relationship 2 Launch Detail: cobas HPV Test Introduce the benefits of the cobas HPV Test 3 ATHENA: In-depth review Communicate importance of the study, GT 16 & 18 4 HPV: Why test women >30 Market expansion 5 Why specify the cobas HPV Test: Branding/brand specification 6 How to talk to patients about the HPV test Service/Relationship 7 Importance of GT 16/18 as risk factors Education 8 Benefits of cobas HPV test to HCPs, labs, patients Branding/brand specification 9 HPV test guideline review Market expansion 10 cobas HPV test v. Competition Branding/brand specification 11 ATHENA Trial: sub-analyses Branding/brand specification 12 HPV: Myths and Facts Market expansion
  • 83. COBAS HPV TEST ONLINE MESSAGING OVERVIEW Month e-Mail e-Detail 1 Introduction to Roche Diagnostics 2 Launch Detail: cobas HPV Test Introduce the benefits of the cobas HPV Test 3 ATHENA: In-depth review 4 HPV: Why test women >30 5 Why specify the cobas HPV Test: 6 How to talk to patients about the HPV test How to talk to patients about the HPV test 7 Importance of GT 16/18 as risk factors 8 Benefits of cobas HPV test to HCPs, labs, patients 9 HPV test guideline review HPV test guideline review 10 cobas HPV test v. Competition 11 ATHENA Trial: sub-analyses 12 HPV: Myths and Facts HPV: Myths and Facts
  • 84. Tactics Qty Cost Total eDetailing Sessions 4 waves at 85K •2 Full 5 Minute Sessions (Est. $85K) 4 73750 $295,000 •2 Mini (2-3) Minute Session (Est $62.5K) eDetailing eMails 12 7200 $86,400 Supplemental email recruitment 8 3500 $28,000 •2 emails per wave eMail Broadcasts (12,000 x 12) 144000 0.45 $64,800 Direct Mail/Web Key (recruitment) 24000 3.50 $84,000 iPad/Tablet Details for Reps 1 85000 $85,000 iPhone App 1 42500 $42,500 Total $685,700 Confidential

Notes de l'éditeur

  1. \n\n
  2. \n
  3. \n
  4. \n
  5. \n
  6. \n
  7. \n
  8. \n
  9. \n
  10. \n
  11. \n
  12. \n
  13. \n
  14. \n
  15. \n
  16. \n
  17. \n
  18. \n
  19. \n
  20. \n
  21. \n
  22. \n
  23. \n
  24. \n
  25. \n
  26. \n
  27. \n
  28. \n
  29. \n
  30. \n
  31. \n
  32. \n
  33. \n
  34. \n
  35. \n
  36. \n
  37. \n
  38. \n
  39. \n
  40. \n
  41. \n
  42. \n
  43. \n
  44. \n
  45. \n
  46. \n
  47. \n
  48. \n
  49. \n
  50. \n
  51. \n
  52. \n
  53. \n
  54. \n
  55. \n
  56. \n
  57. \n
  58. \n
  59. \n
  60. \n
  61. \n
  62. \n
  63. \n
  64. \n
  65. \n
  66. \n
  67. \n
  68. \n
  69. \n
  70. \n
  71. \n
  72. \n
  73. \n
  74. \n
  75. \n
  76. \n
  77. \n
  78. \n
  79. \n
  80. \n
  81. \n
  82. \n
  83. \n
  84. \n
  85. \n
  86. \n
  87. \n
  88. \n
  89. \n
  90. \n
  91. \n
  92. \n
  93. \n
  94. \n
  95. \n
  96. \n
  97. \n
  98. \n
  99. \n
  100. \n
  101. \n
  102. \n
  103. \n
  104. \n
  105. \n
  106. \n
  107. \n
  108. \n
  109. \n
  110. \n
  111. \n
  112. \n
  113. \n
  114. \n
  115. \n
  116. \n
  117. \n
  118. \n
  119. \n
  120. \n
  121. \n
  122. \n
  123. \n
  124. \n
  125. \n
  126. \n
  127. \n
  128. \n
  129. \n
  130. \n
  131. \n
  132. \n
  133. \n
  134. \n
  135. \n
  136. \n
  137. \n
  138. \n
  139. \n
  140. \n
  141. \n
  142. \n
  143. \n
  144. \n
  145. \n
  146. \n
  147. \n
  148. \n
  149. \n
  150. \n
  151. \n
  152. \n
  153. \n
  154. \n
  155. \n\n